耐药相关基因GST-Л、LRP在卵巢上皮性恶性肿瘤组织中的表达及临床意义

The Expression and Clinical Significance of Drug-resistance Genes GST-Л and LRP in Ovarian Carcinoma Tissue

目的:观察卵巢上皮性恶性肿瘤组织中GST-Л、LRP的表达与临床和病理因素的关系。方法:采用免疫组化S P法对30例卵巢上皮性恶性肿瘤组织中的GST-Л和LRP的表达进行检测,分析其表达与病理类型、组织学分级、化疗疗效与预后的关系。结果:①30例卵巢上皮性恶性肿瘤组织中GST Л、LRP的阳性表达率分别为6 6 .6 %、73.3%。②LRP、GST Л在临床Ⅲ～Ⅳ期的阳性表达率分别为99.0 %、76 .5 %,均显著高于Ⅰ～Ⅱ的阳性表达率4 6 .2 %,1 6 .7%。③LRP与GST- Л在G3中的表达率均大于G1～G2 ,但相比差异无显著性;④LRP与GST- Л有共表达现象,两者均强阳性者其化疗效果及预后较差。结论:LRP与GST Л在卵巢上皮性恶性肿瘤中有较恒定的表达,且与临床分期有关,检测两者的表达可预测化疗近期疗效,指导临床化疗方案的选择。

Objective: To study the expression of glutation-S-transferaseЛ (GST-Л) and pulmonary drug-resistant protein (LRP) in ovarian epithelial malignant tumors, and the relationship to clinico-pathology. Methods: 30 cases of ovarian epithelial malignant tumors were included. The expression of GST-Л and LRP were analyzed by immunohistochemistry (S-P), and the relationship between the expression and pathological type, histology differentiation, chemotherapy effect, and prognosis were reviewed. Results: ①The positive expressive rate of GST-Л and LRP was 66.6%, 73.3%, accordingly. ② The positive expressive rate of LRP and GST-Л in stage Ⅲ and Ⅳ was 99% and 76.5%, respectively, which significantly higher than those in stage Ⅰand Ⅱ(46.2%, 16.7%, respectively). ③ The expression rate of LRP and GST-Л in G 3 was higher than in G 1 and G 2, but the difference was no apparent (P>0.05). ④ There existed co-expression in LRP and GST-Л whose strong co-expression predicted poor chemotherapy effect and prognosis. Conclusions: Our study indicated that the LRP and GST-Л express constantly in epithelial ovarian carcinomas. The expression is relevant with the clinical stage. Detection of both of them can predict the shortly chemotherapy effect, and help choose the chemotherapy projects.